Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 2924-2929

  Lee, Ji Eun ^a,b   Lim, Dae Won ^c   Park, Hyun Jun ^a   Shin, Jong Hun ^a   Lee, Seung Min ^a   Oum, Boo Sup ^a,b  

^a Pusan National University Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Lim's Eye Clinic   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; B WAVE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DARK ADAPTATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; ELECTRORETINOGRAPHY; EXPERIMENTAL MODEL; EYE TOXICITY; HISTOPATHOLOGY; LIGHT INTENSITY; LIQUID CHROMATOGRAPHY; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; RABBIT; RETINA DISEASE; SINGLE DRUG DOSE; TRANSMISSION ELECTRON MICROSCOPY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DARK ADAPTATION; ELECTRORETINOGRAPHY; HALF-LIFE; INTRAVITREAL INJECTIONS; MASS SPECTROMETRY; OPHTHALMOSCOPY; RABBITS; RETINA; TETRAZOLES; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 79955977678     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5850     Document Type: Article

References (29)

1. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
2. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
3. Delafontaine P, Lou H. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J Biol Chem. 1993;268:16866-16870.
4. Otani A, Takagi H, Oh H, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci. 2000;41:1192-1199.
5. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2002;86: 311-315.
6. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133:537-543.
7. Wagner J, Jan Danser AH, Derkx FH, et al. Demonstration of rennin mRNA, angiotensinogen mRNA, and angiotensin converting en-zyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996;80:159-163.
8. Danser AH, van den Dorpel MA, Deinum J, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989;68:160-167.
9. Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228:505-509.
10. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol. 1993;25:284-289.
11. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351:28-31.
12. Chaturvedi N, Sjoelie AK, Svensson A; DIRECT Programme Study Group. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst. 2002;3:255-261.
13. Chaturvedi N, Porta M, Klein R, et al.; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372: 1394-1402.
14. Sjølie AK, Klein R, Porta M, et al.; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet. 2008;372:1385-1393.
15. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol. 2004;24:340-345.
16. Sramek SJ, Wallow IH, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin system: immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci. 1992;33:1627-1632.
17. Berka JL, Stubbs AJ, Wang DZ, et al. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci. 1995;36:1450-1458.
18. Shiota N, Saegusa Y, Nishimura K, Miyazaki M. Angiotensin IIgenerating system in dog and monkey ocular tissues. Clin Exp Pharmacol Physiol. 1997;24:243-248.
19. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci. 1999;11:3387-3394.
20. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res. 1998;82:619-628.
21. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985;105:141-145.
22. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoformselective inhibitor. Diabetes. 1997;46:1473-1480.
23. Okada Y, Yamanaka I, Sakamoto T, et al. Increased expression of angiotensin-converting enzyme in retinas of diabetic rats. Jpn J Ophthalmol. 2001;45:585-591.
24. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia. 2002; 45:203-209.
25. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye. 2010;24:1-6.
26. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic difference of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999;33:1406-1413.
27. Kim TH, Moon YS, Chin HS. Change of residual period and clearance rate of intravitreal triamcinolone according to initial injection dosage. J Korean Ophthalmol Soc. 2005;46:1569-1574.
28. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
29. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.